Clinical Use of Naltrexone (EN-1639A): Part I: Safety and Efficacy in Pilot Studies

References

• Baden M. M., Turoff R. S. (1973) Deaths of persons using methadone in New York City. Reported at the 35th Ann. Scientific Meeting, Committee on Problems of Drug Dependence of the National Academy of Sciences, Chapel Hill, NC, 1971
   Google Scholar
• Blachly P. H., David N. A., Irwin S. 1-alpha-acetylmethadol (LAM): comparison of laboratory findings, electroencephalograms, and Cornell Medical Index of patients stabilized on LAM with those on methadone. 4th Nat. Conf: on Methadone Treatment Proc. 1972; 203–205
   Google Scholar
• Kreek M. J. Medical safety and side effects of methadone in tolerant individuals,. JAMA 1973; 223: 665–668
   PubMed Web of Science ®Google Scholar
• Chappel J. N., Senay E. C., Jaffe J. H. Cyclazocine in a multimodality treatment program: comparative results,. Int. J. Addict. 1971; 6: 509–513
   Web of Science ®Google Scholar
• Martin W. R., Gorodetzky C. W., McClane T. K. A proposed method for ambulatory treatment of narcotic addicts using a long-acting orally effective narcotic antagonist, cyclazocine: an experimental study. Presented to Committee on Problems of Drug Dependence, National Research Council. 1965
   Google Scholar
• Wikler A. Conditioning factors in opiate addiction relapse. Narcotics, D. M. Wilner, G. G. Kassebaum. McGraw-Hill, New York 1965; 85–100
   Google Scholar
• Martin W. R., Gorodetzky C. W., McClane T. K. An experimental study in the treatment of narcotic addicts with cyclazocine,. Clin. Pharmacol. Ther. 1966; 7: 455–465
   PubMed Web of Science ®Google Scholar
• Jaffe J. H. Cyclazocine in the treatment of narcotic addiction,. Curr. Psychiat. Ther. 1967; 7: 147–156
   PubMedGoogle Scholar
• Himmelsbach C. K. Clinical studies of drug addiction,. Arch. Intern. Med. 1942; 69: 766, 772
   Google Scholar
• Martin W. R., Wikler A., Eades C. G., Pescor F. T. Tolerance to and physical dependence on morphine in rats,. Psychopharmacologia 1963; 4: 247–260
   PubMed Web of Science ®Google Scholar
• Pohl J. Uber das N-allynorcodein, einen antagonisten des morphenes, as reported in A. 1973, Wikler, Report of the APA Task Force on Methadone Maintenance and Narcotic Blocking Drugs: Part II-Narcotic Blocking Drugs
   Google Scholar
• McCawley E. L., Hart E. R., Marsh D. F. The preparation of N-allylnormorphone,. J. Amer. chem. Soc. 1941; 63: 314
   Google Scholar
• Weijlard J., Erickson A. E. N-allylnormorphine,. J. Amer. Chem. Soc. 1942; 64: 869–870
   Google Scholar
• Martin W. R., Gorodetzky C. W. Demonstration of tolerance to and physical dependence on N-allylnormorphine (nalorphine),. J. Pharmacol. Exp. Ther. 1965; 152: 437–442
   Google Scholar
• Kissin B., et al. Cyclazocine treatment for heroin addicts. Proc. 5th Nat. Conk on Methadone Treatment. 1973; Vol. 1: 658–666
   Google Scholar
• Kleber H. D., et al. The use of cyclazocine in treating narcotic addicts in low-intervention setting,. Arch. Gen. Psychiat. 1974; 30: 37–42
   PubMed Web of Science ®Google Scholar
• Schoof K., Hersch R. Side effects of cyclazocine,. Narcotic Antagonist Res. Rev. 1973; 1: 2–3
   Google Scholar
• Freedman A. M., Fink M., Sharoff R., Zaks A. Clinical studies of cyclazocine in the treatment of narcotic addiction,. Amer. J. Psychiat. 1968; 124: 1499–1504
   PubMed Web of Science ®Google Scholar
• Martin W. R., Fraser H. F., Gorodetzky C. W., Rosenberg D. E. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclapropylmethyl 2-hydroxy-5, 9-dimethyld, 6-benzomorphan (cyclazocine, WN-20, 740, ARC II-C3),. J. Pharmacol. Exp. Ther. 1965; 150: 426–436
   PubMed Web of Science ®Google Scholar
• Jasinski D. R., Martin W. R., Haertzen C. A. The human pharmacology and abuse potential of N-allylnormorphone (naloxone),. J. Pharmacol. Exp. Ther. 1967; 157: 420–426
   PubMed Web of Science ®Google Scholar
• Kurland A. A., et al. Naloxone and the narcotic abuser: a low dose maintenance program,. Int. J. Addict. 1973; 8: 127–141
   PubMed Web of Science ®Google Scholar
• Fink M., et al. Naloxone in human dependence,. Clin. Pharmacol. Ther. 1968; 9: 568–577
   PubMed Web of Science ®Google Scholar
• Zaks A., Jones T., Fink M., Freedman A. M. Naloxone treatment of opiate dependence,. JAMA 1971; 215: 2108–2110
   PubMed Web of Science ®Google Scholar
• Resnick R. B., Fink M., Freedman A. M. Cyclazocine treatment of opiate dependence: a progress report,. Comp. Psychiat. 1971; 12: 491–502
   PubMed Web of Science ®Google Scholar
• Blumberg H., Pachter F. J., Matossian Z., U. S. patent 3,332,950, July 25, 1967
   Google Scholar
• Blumberg N., Dayton H. B. Narcotic antagonist studies with EN-1639A (N-cyclopropylnoroxymorphone hydrochloride). 5th Internat. Congr. on Pharmacology, abstracts of volunteer papers, the Congress. 1972; 23
   Google Scholar
• Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone, an antagonist in the treatment of heroin dependence,. Arch. Gen. Psychiat. 1973; 28: 784–791
   PubMed Web of Science ®Google Scholar
• Resnick R. B., et al, Studies of EN-1639A (naltrexone)-a new narcotic antagonist, In Press
   Google Scholar
• Martin W. R., Sandquist V. L. A sustained release depot for narcotic antagonists,. Arch. Gen. Psychiat. 1974; 30: 31–33
   PubMed Web of Science ®Google Scholar
• Cone E. J. Human metabolite of naltrexone (N-cyclopropylmethylnoroxymorphone) with a novel C-6 morphone configuration,. Tetrahedron Lett. 1973; 28: 2607–2610
   Google Scholar
• Cone E. S., Yeh S. Y., Gorodetzky C. W. Human metabolism of naltrexone,. The Pharmacologist 1973; 15: 242
   Google Scholar
• Investigators Brochure, EN-1639A (naltrexone). Endo Laboratories, Inc., Garden City, NY 1973
   Google Scholar